about
Alternative methods to analyse the impact of HIV mutations on virological response to antiviral therapyT-cell activation discriminates subclasses of symptomatic primary humoral immunodeficiency diseases in adultsVirological and immunological response in HIV-1-infected patients with multiple treatment failures receiving raltegravir and optimized background therapy, ANRS CO3 Aquitaine CohortPrevalence and effect of pre-treatment drug resistance on the virological response to antiretroviral treatment initiated in HIV-infected children - a EuroCoord-CHAIN-EPPICC joint project.Integrative Analysis of Immunological Data to Explore Chronic Immune T-Cell Activation in Successfully Treated HIV Patients.Impact of CD4 and CD8 dynamics and viral rebounds on loss of virological control in HIV controllersMethodological issues in the use of composite endpoints in clinical trials: examples from the HIV field.Effect of coinfection with hepatitis C virus on survival of individuals with HIV-1 infection.Temporal trends in prognostic markers of HIV-1 virulence and transmissibility: an observational cohort study.Efficacy and safety of direct-acting antiviral regimens in HIV/HCV-co-infected patients - French ANRS CO13 HEPAVIH cohort.No significant effect of cannabis use on the count and percentage of circulating CD4 T-cells in HIV-HCV co-infected patients (ANRS CO13-HEPAVIH French cohort).Triple therapy with boceprevir or telaprevir in a European cohort of cirrhotic HIV/HCV genotype 1-coinfected patients.All-oral Direct-acting Antiviral Regimens in HIV/Hepatitis C Virus-coinfected Patients With Cirrhosis Are Efficient and Safe: Real-life Results From the Prospective ANRS CO13-HEPAVIH Cohort.Inhibition of protein kinase C phosphorylation of hepatitis B virus capsids inhibits virion formation and causes intracellular capsid accumulation.CD4:CD8 Ratio and CD8 Count as Prognostic Markers for Mortality in Human Immunodeficiency Virus-Infected Patients on Antiretroviral Therapy: The Antiretroviral Therapy Cohort Collaboration (ART-CC).Serum ST2 level is an independent predictor of all-cause mortality in HIV-infected patients. Aquitaine Cohort, France.Short article: Anger and quality of life in patients co-infected with HIV and hepatitis C virus: a cross-sectional study (ANRS CO13-HEPAVIH).Late presentation for HIV care across Europe: update from the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study, 2010 to 2013.Activation, senescence and inflammation markers in HIV patients: association with renal function.Characterization of Biomarkers of Tumorigenic and Chemoresistant Cancer Stem Cells in Human Gastric Carcinoma.Short article: Fatigue in the long term after HCV treatment in HIV-HCV-coinfected patients: functional limitations persist despite viral clearance in patients exposed to peg-interferon/ribavirin-containing regimens (ANRS CO13-HEPAVIH cohort).Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimen.Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART.Association of immune-activation and senescence markers with non-AIDS-defining comorbidities in HIV-suppressed patients.HCV viral load at baseline and at week 4 of telaprevir/boceprevir based triple therapies are associated with virological outcome in HIV/hepatitis C co-infected patients.The negative impact of HBV/HCV coinfection on cirrhosis and its consequences.Daily cannabis and reduced risk of steatosis in human immunodeficiency virus and hepatitis C virus co-infected patients (ANRS CO13-HEPAVIH).Protective effect of coffee consumption on all-cause mortality of French HIV-HCV co-infected patients.Dynamic and rapid changes in viral quasispecies by UDPS in chronic hepatitis C patients receiving telaprevir-based therapy.Hepatitis C virus (HCV) protease variability and anti-HCV protease inhibitor resistance in HIV/HCV-coinfected patients.HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virological failure on raltegravir-containing regimens.Analysis of RT sequences of subtype C HIV-type 1 isolates from indian patients at failure of a first-line treatment according to clinical and/or immunological WHO guidelines.Evolution of 2-long terminal repeat (2-LTR) episomal HIV-1 DNA in raltegravir-treated patients and in in vitro infected cells.Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study.Role of hepatitis B virus genetic barrier in drug-resistance and immune-escape development.Rapid Adenovirus typing method for species identification.Effect of cytomegalovirus-induced immune response, self antigen-induced immune response, and microbial translocation on chronic immune activation in successfully treated HIV type 1-infected patients: the ANRS CO3 Aquitaine Cohort.Impaired patient-reported outcomes persist in HIV-HCV co-infected patients and in cirrhotic patients despite HCV clearance.The impact of coffee consumption on fibrosis and steatosis in HIV-HCV co-infected patients.End-Stage Liver Disease in HIV Infection: An Avoidable Burden?
P50
Q33378828-E3514763-FCFF-49A3-86AC-560280D5B0D5Q33559219-15025DD7-94F5-42EC-8613-8FFBDFCC8DBAQ33910771-57795ADD-B903-4BA0-8A83-78C91032F4CBQ36186007-D0F45762-6A7D-4E90-BB35-03149DA5B676Q36238363-390FF488-E5C5-4559-AE3E-1796E8254647Q36336077-35E609A2-6F4C-4D4A-9DB4-4B95F3F19022Q37692734-253957BC-3014-43D7-B5C6-DB5E20376067Q38405321-616CCB65-BCEE-4996-82B0-F71170E82A27Q38412142-9B78A759-67C2-4FFB-ABA1-C708AA758724Q38943318-9B0F637D-484D-4A9B-88A1-BFDA032AF029Q39213852-39BFCBE8-AA98-4256-BEA3-60E5933362B7Q39249225-AB1DDD6D-FBC9-4DE0-B226-FD7A7239DA5CQ39673593-F815727F-77F9-42EF-B1E1-2D933C92F2C7Q39746875-586A4739-838D-45DF-95E4-746B58FFF30DQ40043083-C71111E4-1DE0-4ADF-BF15-49A59A640FF5Q40073034-6787EC49-045C-4E86-A479-D7D8B5D7E48BQ40238516-40BAB91C-49BE-4A2C-BB35-692E2BB2BADEQ40255064-8F454C9C-559F-4405-B26E-9CF0629BBBBBQ40280840-2BE172CB-A746-4838-AD45-33ABB281365BQ40543081-87FB4F08-44E6-4C18-8185-FF297249191DQ40675596-7F31BAB9-77E9-42EB-BD60-06FB02A86C8FQ40812700-507B530A-A014-45EA-A091-B2FE70117C13Q40857943-4363F65B-4945-4020-8C4B-5481481B9046Q40920026-718F3D90-34F3-46DF-8A07-ACB51FB4F6F2Q40925361-31B7D2B3-C970-4B54-89A1-7F028BBCD0B3Q41921105-ECF2ED62-4CB3-4EC4-AF45-E25041F32FBDQ41923080-25F9378E-3638-461A-9CB5-D1DE8AED035DQ41931138-75D05852-4E11-403C-9925-C926F4A9AF5DQ42992466-F8423FD9-929D-40B3-97C5-C28C12152266Q43035245-0E940AD8-0AE3-4E01-B395-43642D053385Q43101053-C9329363-7847-4A28-87EC-B0F8D2A1397BQ43119913-031C8CA7-A23F-4ADE-B54D-61E469CEBA58Q43201835-8D32C8EC-891D-46AD-AB7E-0F944F4F59E0Q45057839-33567A8E-A5AF-41FA-B4B0-BED0F3D55C09Q45364246-9B944CA4-A428-4A4A-8E5C-BD387138183CQ46305895-255D37AC-A123-4F61-B217-4C080F3A4512Q46753948-7650D580-72FB-4D7B-A447-3A7DB8A6737AQ47597168-9EE537E4-B1F1-493B-BEDF-29A36AD4DBF6Q50148402-D6D55DB9-6037-4D51-8FD3-6791467FB775Q50777220-9F8711C1-37B4-40CD-948B-7B70BC0D4D70
P50
description
hulumtuese
@sq
researcher
@en
ricercatrice
@it
wetenschapper
@nl
հետազոտող
@hy
name
Linda Wittkop
@ast
Linda Wittkop
@en
Linda Wittkop
@es
Linda Wittkop
@nl
Linda Wittkop
@sl
type
label
Linda Wittkop
@ast
Linda Wittkop
@en
Linda Wittkop
@es
Linda Wittkop
@nl
Linda Wittkop
@sl
prefLabel
Linda Wittkop
@ast
Linda Wittkop
@en
Linda Wittkop
@es
Linda Wittkop
@nl
Linda Wittkop
@sl
P214
P1053
E-3319-2014
P106
P21
P214
P31
P3829
P496
0000-0003-2403-0960
P735
P7859
viaf-43037005